The primary goal of this study is to examine whether recurrence of HPV-associated OPSCC can be predicted by two factors: 1) mutations in genes called TRAF3 and CYLD, and 2) measurements of circulating HPV DNA in blood plasma. The study will also investigate whether HPV integration is associated with TRAF3 and CYLD mutations, and whether recurrence prediction improves when looking at HPV integration along with TRAF3 and CYLD mutations.
The study involves collecting tumor and blood samples, and quality of life assessments.
100% Remote (online, phone, text)
Wendell Yarbrough
Radiation Oncology - Chapel Hill
Clinical or Medical
Observational
Cancer (Head and Neck)
20-2065